Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC.

ABSTRACT: EGFR mutant non-small cell lung cancer patients' disease demonstrates remarkable responses to EGFR-targeted therapy, but inevitably they succumb to acquired resistance, which can be complex and difficult to treat. Analyzing acquired resistance through broad molecular testing is crucial to understanding the resistance mechanisms and developing new treatment options. We performed diverse clinical testing on a patient with successive stages of acquired resistance, first to an EGFR inhibitor with MET gene amplification and then subsequently to a combination EGFR and MET targeted therapies. A patient-derived cell line obtained at the time of disease progression was used to identify NRAS gene amplification as an additional driver of drug resistance to combination EGFR/MET therapies. Analysis of

SUBMITTER: Peters TL 

PROVIDER: S-EPMC8511249 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature